Advanced Therapy Medicinal Products (ATMP) Market Size, Share And Forecast To 2031


(MENAFN- Straits Research) Advanced therapy medicinal products (ATMPs) are a novel class of heterogeneous, research-driven biopharmaceuticals. They are being created with assistance from the European Union (EU) and the United States. ATMPs are regulated as biological products in both zones, establishing the legal basis for their production. The European Union has four main categories of advanced therapies: gene therapy, somatic cell therapy, tissue-engineered therapies, and combined advanced therapies. However, the subcategorization of these therapies varies by region.
Market Dynamics
Benefits Over Conventional Therapies Drive the Global Market
ATMPs, over the long term, can substantially improve the health and quality of life of patients with life-threatening diseases. They are utilized specifically for disorders with few or no alternative treatments. Patients who undertake invasive procedures frequently for symptom relief have also benefited from ATMPs. Therefore, using ATMPs can enhance patient health and quality of life, benefiting caregivers, families, and society by alleviating physical, emotional, and monetary burdens.
Additionally, ATMPs can prevent the need for costly procedures such as blood transfusion and enzyme replacement therapy, thereby reducing expenditures on apparatus and training for medical personnel and nursing staff who perform these complex procedures. Moreover, patients treated with ATMPs tend to experience fewer co-morbidities that necessitate costly therapies and support. Therefore, these benefits provided by ATMPs are anticipated to promote market expansion.
Increased Financing for Gene and Cell Therapy Creates Tremendous Opportunities
Numerous opportunities for market expansion are anticipated to result from an increase in financing and investments in ATMPs. For example, in July 2019, Bayer provided USD 215 million to the U.S. biotechnology startup Century Therapeutics to develop therapies for solid tumors and blood cancer. Versant Ventures and Fujifilm Cellular Dynamics each contributed USD 35 million, bringing the total amount of funding to USD 250 billion. Similarly, Allogene Therapeutics, a biotechnology company based in California, raised over USD 300 million in 2018 for its allogeneic product pipeline. The company develops CAR T-cell therapeutics for solid tumors and cancers of the blood.
Regional Analysis
North America is the most significant global advanced therapy medicinal products (ATMP) market shareholder and is anticipated to exhibit a CAGR of 12.6% during the forecast period. North America's leading revenue share is due to factors such as a robust regulatory framework for promoting cellular therapy development, the high cost of therapies in the United States, and many regional companies. Federal investments in expanding advanced therapy research in the region are anticipated to contribute to expanding the North American stem cell therapy market. In addition, the market is anticipated to be driven by organizations such as the International Society for Cellular Therapy, a global society of technologists, regulators, clinicians, and industry partners whose mission is to improve the safety and efficacy of cellular therapies to enhance patient outcomes.
Asia-Pacific is estimated to exhibit a CAGR of 8.2% over the forecast period. Asia-Pacific's ATMP market, led by Japan, China, and South Korea, has gained momentum internationally in recent years. Biotech companies from other regions concentrate on creating novel therapies by increasing their technologies and presence in the Asia-Pacific region. For instance, Merck and GenScript formed a strategic alliance in March 2019 to manufacture gene and cell therapies. Under the terms of this partnership, Merck would provide manufacturing services to GenScript. In addition, global companies are forming partnerships with domestic firms. For instance, Pluristem Therapeutics Inc. partnered with CHA Bio of South Korea. According to the terms of the collaboration, CHA would conduct and fund multiple PLacental eXpanded (PLX) cell-based clinical trials for the latter. Such collaborations drive market growth.
Key Highlights

The global advanced therapy medicinal products (ATMP) market was valued at USD
8.40 billion in 2022. It is estimated to reach USD 20.63 billion by 2031, growing at a CAGR of 10.5% during the forecast period (2023–2031).
Based on therapy type, the global advanced therapy medicinal products (ATMP) market is segmented into cell therapy, gene therapy, CAR-T therapy, and tissue-engineered product.
The tissue-engineered product segment owns the highest market share and is predicted to exhibit a CAGR of 6.5% during the forecast period.
North America is the most significant global advanced therapy medicinal products (ATMP) market shareholder and is anticipated to exhibit a CAGR of 12.6% during the forecast period.

Competitive Players
The key global advanced therapy medicinal products (ATMP) market players are Spark Therapeutics, Inc., Bluebird Bio, Inc., Novartis AG, UniQure N.V., Celgene Corporation, Gilead Lifesciences, Inc., Kolon TissueGene, Inc., JCR Pharmaceuticals Co., Ltd., MEDIPOST, Vericel Corporation, PHARMICELL Co., Ltd, Organogenesis Inc., and others.
Market News

In October 2022, The European Medicines Agency (EMA) announced that it is preparing to launch a pilot program designed to assist advanced therapy medicinal product (ATMP) scientists in navigating regulatory challenges throughout the research process, from initial investigation to the development of medicines, to assist non-profits in addressing unmet clinical needs and advancing ground-breaking research for EU patients.
In September 2022, Myrtelle Inc., a clinical-stage gene therapy firm that develops transformative treatments for neurodegenerative diseases, revealed that the European Medicines Agency (EMA) had categorized the firm's lead gene therapy product candidate, rAAV-Olig001-ASPA to treat Canavan disease, as an Advanced Therapy Medicinal Product (ATMP), specifically a Gene Therapy Medicinal Product (GTMP).

Global Advanced Therapy Medicinal Products (ATMP) Market: Segmentation
By Therapy Type

Cell Therapy
Gene Therapy
CAR-T Therapy
Tissue Engineered Product

By Regions

North America
Europe
Asia-Pacific
Rest of the World

MENAFN09072024004597010339ID1108421699


Straits Research

Legal Disclaimer:
MENAFN provides the information “as is” without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the provider above.